Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-GPRC5D/anti-CD3 bispecific antibody LBL-034

A humanized immunoglobulin G1 (IgG1) bispecific monoclonal antibody directed against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential immunomodulating and antineoplastic activities. Upon administration, anti-GPRC5D/anti-CD3 bispecific antibody LBL-034 binds to both CD3 on T cells and GPRC5D expressed on tumor cells. This results in the cross-linking of T cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors while minimally expressed on normal, healthy cells. It plays a key role in tumor cell proliferation.
Synonym:anti-CD3/anti-GPRC5D bispecific monoclonal antibody LBL-034
anti-GPRC5D/CD3 bispecific antibody LBL-034
GPRC5D x CD3 bispecific antibody LBL-034
Code name:LBL 034
LBL-034
LBL034
Search NCI's Drug Dictionary